The FDA on Wednesday granted EliLilly’s selective RET kinase inhibitor Retevmo (selpercatinib) accelerated approval to treat children two years and older with certain RET-mutated thyroid and solid tumours. According to the US regulator, it’s the first targeted cancer therapy for paediatric patients younger than 12 with RET alterations.
The RET inhibitorRET inhibitor already holds accelerated approval for the thyroid cancer indications in adults and paediatric patients older than 12, as well as the solid tumour indication in adults.
Supporting data
The new paediatric approval was based on results of the Phase I/II LIBRETTO-121 study in 25 patients ages 2 to 20 with locally advanced or metastatic RET-activated solid tumours non-responsive to available therapies.
Retevmo led to a confirmed overall response rate (ORR) of 48%. Additionally, the median duration of response (DOR) was not reached, with 92% of responders still seeing a treatment effect at 12 months.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.